Skip to main content
Skip to main content
Home
About Us
Overview
Senior Leadership
Board of Directors
Advisory Board
Our Medicine
Talicia®
Expanded Access
Pipeline
Pipeline
Pipeline
Opaganib
RHB-204
RHB-107
RHB-102
Gastroenteritis & Gastritis
IBS-D
Oncology Support
Medical Grant & Investigator Initiated Study Requests
Investigator Initiated Study Requests
Medical Grant/Sponsorship
Medical Information
News
Investors
Overview
Events & Presentations
Press Releases
Financial Filings
Financial Reports
Annual Reports
SEC Filings
Stock Information
Stock Information
Analyst Coverage
Corporate Governance
Governance Documents
Partnering
Careers
Overview
Benefits
Contact
Contact Us
Email Alerts
News
Home
About Us
Overview
Senior Leadership
Board of Directors
Advisory Board
Our Medicine
Talicia®
Expanded Access
Pipeline
Pipeline
Pipeline
Opaganib
RHB-204
RHB-107
RHB-102
Gastroenteritis & Gastritis
IBS-D
Oncology Support
Medical Grant & Investigator Initiated Study Requests
Investigator Initiated Study Requests
Medical Grant/Sponsorship
Medical Information
News
Investors
Overview
Events & Presentations
Press Releases
Financial Filings
Financial Reports
Annual Reports
SEC Filings
Stock Information
Stock Information
Analyst Coverage
Corporate Governance
Governance Documents
Partnering
Careers
Overview
Benefits
Contact
Contact Us
Email Alerts
Back to all news
Mr. Gilead Raday's interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)
February 2, 2012
Download
(opens in new window)
PDF 8 KB
Mr. Gilead Raday's interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)
Multimedia Files:
Back to all news